Extramammary Paget disease

What causes extramammary Paget disease?

The cause of extramammary Paget disease (EMPD) remains unknown. Approximately 25% of cases are associated with an underlying tumor. The type of tumor that is most likely to be associated with this disease is an apocrine carcinoma. Other associated cancers include cutaneous adnexal carcinoma and carcinoma of the Bartholin glands, urethra, bladder, vagina, cervix, endometrium, or prostate. About 4-7% of patients with genital disease have an associated carcinoma. Perianal disease is associated with underlying colorectal cancer in 25-35% of cases.

Last updated on 05-01-20

How is extramammary Paget disease diagnosed?

The diagnostic process for extramammary Paget disease (EMPD) should begin with a detailed review of systems and physical examination. Initial examinations could additionally include: full skin examination, palpation of all lymph nodes, rectal examination, sigmoidoscopy, cystoscopy.

When EMPD is suspected, the diagnosis is typically confirmed via skin biopsy of the lesion. Under the microscope, the presence of Paget cells along with other specific findings confirms the diagnosis. Special stains may be necessary to distinguish EMPD from early melanoma (melanoma in situ).

Last updated on 05-01-20

What is the prognosis for extramammary Paget disease?

The prognosis for extramammary Paget disease (EMPD) depends on early diagnosis and surgical treatment. The prognosis is good for cases where the disease only affects the epidermal (top) layer of skin and the areas around the surgically removed lesion (margins) remain free of the disease. One study showed a mortality rate of 18% for patients without associated carcinoma and 46% for those with underlying carcinoma. Perianal disease, invasion into the dermal skin layer, and spread of cancer to lymph nodes are more likely to be associated with a poor prognosis. The rate of recurrence is approximately 30%. In those people who experience a recurrence of extramammary Paget disease, the average time it takes for the disease to recur is 2.5 years.

Last updated on 05-01-20

How might extramammary Paget disease be treated?

Extramammary Paget disease (EMPD) is usually treated by surgically removing the skin lesion. It is sometimes difficult to determine how much skin should be removed, particularly when lesions are spread throughout the anogenital region. Because recurrence is common, it is standard for patients to be re- examined every 3 months after surgery for the next 2 years. After 2 years, annual follow-ups are usually recommended.

In cases where surgery is not a possibility due to recurrence or location; treatment options reported in the medical literature with varying levels of success include: chemotherapeutic agents such as 5-fluorouracil, imiquimod, paclitaxel, trastuzumab, and docetaxel as well as aminolevulinic acid photodynamic therapy, laser ablation, and radiation therapy. Unfortunately, studies regarding the effectiveness of the above treatment options are limited to mainly case studies and small literature reviews with limited follow-up.

Promising studies published recently include a study completed in Japan that reviewed the use of docetaxal as a first-line treatment in 13 individuals with EMPD with metastasis. 12 individuals were found to have a response to treatment with a disease control rate estimated to be 83%. Another promising study reviewed the use of imiquimod in 10 cases of EMPD of the vulva. Complete clinical remission was reported in 9 individuals. The remaining individual had partial remission.

There is an ongoing research study focused on evaluating the effectiveness of imiquimod in the treatment of EMPD. To learn more about this trial, please click on the following link through ClinicalTrials.gov

Last updated on 05-01-20

Connect with other users with Extramammary Paget disease on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App